Hypomethylating agent based combinations in higher risk myelodysplastic syndrome
- 9 December 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (5), 1012-1027
- https://doi.org/10.1080/10428194.2019.1697812
Abstract
For over a decade the hypomethylating agents (HMA) azacitidine and decitabine have been the mainstay of therapy for myelodysplastic syndrome (MDS). There is a critical need to improve frontline therapy, given that only up to half of high-risk MDS patients will respond to HMA therapy, and responses are short-lived. Currently, a key strategy has been to combine HMAs with other novel agents to improve patient outcomes. While synergy of agents is the goal of combination therapy, combinations often come at the cost of increased side effects that are often intolerable in this vulnerable population. The purpose of this review is to critically examine clinically relevant HMA combinations and discuss the future of MDS management.This publication has 118 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaGenes & Development, 2012
- A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Blood, 2011
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeThe New England Journal of Medicine, 2009
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndromeExperimental Hematology, 2007
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006